Causality is a tricky business in pharmacovigilance. With limited numbers of adverse event reports, how are we supposed to draw conclusions about causal relationships?

The UK Academy of Medical Sciences recommends major changes in how medical research is managed and communicated and the importance of scientific evidence in decision making.

Emerging ideas in the philosophy of science challenge a rigid reliance on evidence-based medicine, offering a more nuanced understanding of causal dispositions and patient safety.

Real-world data is a rich source of evidence for pharmacovigilance, but there are challenges yet to be faced before unlocking its true potential as a resource.

In this digital age, can pharmacovigilance experts leverage on new types of data to find evidence for signals? Listen to the latest Drug Safety Matters podcast to find out.

The new episode of the Drug Safety Matters podcast is here. Find why pharmacovigilance scientists should not discount the value of intuition.